Protocols

Tirzepatide produces meaningfully greater weight loss than semaglutide. The 2025 SURMOUNT-5 head-to-head RCT found body-weight reductions of 20 percent versus 14 percent at 72 weeks in adults with obesity without type 2 diabetes. GI-related discontinuations were lower with tirzepatide. Pooled meta-analytic data show elevated SAE rates in type 2 diabetes populations but comparable rates in the obesity-only SURMOUNT-5 cohort.

Gray-market retatrutide users achieve less than half the weight loss of trial participants, based on an August 2026 EHR preprint of 652 patients that found 7·2% mean body-weight reduction at 6–12 months versus 15·5% in a matched trial cohort, with tachycardia rates 2·88 times higher in the gray-market group.

The FAERS record for BPC-157 is thin but not empty. The FDA's July 2026 PCAC briefing cites compounded BPC-157 case reports, with the only controlled human study documenting headache and flatulence after rectal administration. Serious adverse events in the broader compounded peptide category include rhabdomyolysis, sympathomimetic toxidrome, and posterior reversible encephalopathy syndrome; per-compound attribution is limited by spontaneous-reporting quality.

The 2026 Yuan review in International Journal of Molecular Sciences reveals a clear evidence hierarchy: gastrointestinal mucosa holds the most mature data, including an unpublished human Phase II trial; tendon and ligament follow with robust preclinical biomechanical evidence; muscle, bone, and peripheral nerve occupy a middle tier; and cartilage remains the least characterised tissue type for BPC-157 repair activity.

The 2026 Schultze review in Pain Medicine (Oxford Academic) maps BPC-157 against the full spectrum of peptide-based analgesics — from FDA-approved ziconotide and CGRP-targeting monoclonal antibodies to investigational compounds. For BPC-157, the review identifies a single human pain dataset: a 2021 retrospective case series reporting 91.6% knee pain improvement with intra-articular injection; no further human pain studies have followed.

Yes. In the Phase 3 LUCIDITY trial reported in August 2026, avexitide 90 mg subcutaneously once daily reduced the composite rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo (p=0.000003) in adults with PBH following RYGB. The trial met its FDA-agreed primary endpoint and all pre-specified secondary endpoints, with a generally favourable tolerability profile.

The 2026 Yuan review in International Journal of Molecular Sciences reveals a critical design constraint: BPC-157's analgesic mechanisms peak early through eNOS-mediated nitric oxide modulation and cytokine suppression, while its structural repair cascade unfolds over days to weeks. Aligning route, timing, and injury phase to both endpoints requires understanding where those pathways converge and where they diverge.

Compounding or selling retatrutide outside a registered clinical trial is both federally illegal and clinically unsafe in 2026. The FDA has explicitly stated that retatrutide cannot be legally compounded under either the 503A or 503B pathways. No reference standard exists for purity verification, and Eli Lilly has filed multiple lawsuits against companies selling the compound illicitly.

The FDA's Pharmacy Compounding Advisory Committee voted in favour of adding six peptides — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax — to the 503A bulk list in July 2026, overriding staff opposition. That vote is non-binding and changes nothing in current law. For four of the six, the FDA's own briefing documents found no human safety studies at all.

A 2025 PNAS study from Yale found that semaglutide recruits — rather than silences — AgRP hunger neurons in female mice, and that this recruitment is required for the drug's full weight-lowering effect. A parallel JCI study confirmed rapid AgRP inhibition at pharmacologic doses, revealing a context-dependent, bidirectional relationship between GLP-1 receptor agonists and hypothalamic hunger circuitry.

Neither BPC-157 nor TB-500 has completed a human randomised controlled trial for ulcerative colitis, wound healing, or pain as of 2026. FDA staff concluded the evidence was inadequate for all three indications. An advisory committee nonetheless voted 8-6 in favour of adding both to the 503A compounding list — a non-binding recommendation that has not yet changed legal compounding status.

As of 2026, the human dose-response record for BPC-157 consists of a Phase 1 tolerability study in two healthy adults, an unpublished Phase 2 enema trial in ulcerative colitis, and a small number of soft-tissue case series. No dose-response curve has been established in humans for any indication. FDA reviewers characterised the available data as sparse, short, and exploratory.